The importance of CASP8 in TRAIL resistance in gliomas has been reported as well [23], while the data of other studies have strongly suggested TRAIL sensitivity to be CASP8-independent and DR4-specific [21]. The gene discussed is TNFRSF10A; the disease is central nervous system cancer.